NervGen Pharma Corp. Common stock

FRC's fair value estimate for NervGen Pharma Corp. Common stock, and the rating behind it. NGEN last traded at $2.05; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Valuation, profitability, liquidity and leverage ratios for NervGen Pharma Corp. Common stock. Starting points for NervGen Pharma Corp. Common stock: EPS -$0.60, beta 0.73. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend history, yield and payout sustainability for NervGen Pharma Corp. Common stock. NervGen Pharma Corp. Common stock does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Reported vs. expected earnings history for NervGen Pharma Corp. Common stock. Trailing twelve-month EPS for NervGen Pharma Corp. Common stock stands at -$0.60. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Income statement, balance sheet and cash flow history for NervGen Pharma Corp. Common stock. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

NervGen Pharma Corp. Common stock valued side by side against its closest peers. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Which institutions hold NervGen Pharma Corp. Common stock, and how their positions are changing. At a $168.5M market value, institutional positions materially move NervGen Pharma Corp. Common stock's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Buying and selling by NervGen Pharma Corp. Common stock executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

U.S. Senate disclosures naming NervGen Pharma Corp. Common stock. NervGen Pharma Corp. Common stock is a $168.5M company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

U.S. House of Representatives disclosures naming NervGen Pharma Corp. Common stock. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

Latest headlines and company announcements for NervGen Pharma Corp. Common stock. Press releases and market coverage, newest first.